LLY AI Stock Analysis – Buy, Hold, or Avoid?
Eli Lilly and Company (LLY)
Fundamentals
Eli Lilly's fundamentals remain exceptionally strong, driven by robust revenue growth, improving margins, and consistent outperformance of earnings expectations. The company's profitability, return metrics, and operational leverage highlight a business with both scale and high efficiency, although a premium valuation may limit short-term upside potential.
Financial Highlights
Growth Metrics
Profitability Metrics
Technical Analysis
LLY is currently in a strong uptrend with solid momentum, trading above key moving averages after a golden cross formation. The stock shows neutral RSI levels indicating balanced momentum without overbought or oversold extremes. Price action is supported by strong trend indicators, positioning LLY in the advancing phase with institutional accumulation.
No extreme reading
Price in uptrend
Strong trend active
50 above 200 - bullish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Eli Lilly's fundamentals remain exceptionally strong, driven by robust revenue growth, improving margins, and consistent outperformance of earnings expectations. The company's profitability, return metrics, and operational leverage highlight a business with both scale and high efficiency, although a premium valuation may limit short-term upside potential.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$8.55
Estimated
$6.97
Surprise
+$1.58
Surprise %
+22.67%
Revenue
Actual
$19.8B
Estimated
$17.82B
Surprise
+$1.98B
Surprise %
+11.11%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $8.55 | $7.54 | $7.02 | $6.31 | $3.34 | $5.32 | $1.18 | $3.92 |
| EPS (Estimated) | $6.97 | $6.91 | $5.69 | $5.60 | $3.26 | $5.03 | $1.47 | $2.60 |
| EPS Surprise | +$1.58 | +$0.63 | +$1.33 | +$0.71 | +$0.08 | +$0.29 | -$0.29 | +$1.32 |
| % Diff | +22.7% | +9.1% | +23.4% | +12.7% | +2.5% | +5.8% | -19.7% | +50.8% |
| Revenue | ||||||||
| Revenue (Actual) | $19.8B | $19.29B | $17.6B | $15.56B | $12.73B | $13.53B | $11.44B | $11.3B |
| Revenue (Estimated) | $17.82B | $17.94B | $16.05B | $14.7B | $12.67B | - | $12.1B | $9.98B |
| Revenue Surprise | +$1.98B | +$1.35B | +$1.55B | +$853.57M | +$61.12M | - | -$658.68M | +$1.32B |
| % Diff | +11.1% | +7.5% | +9.6% | +5.8% | +0.5% | - | -5.4% | +13.2% |
Valuation
Eli Lilly (LLY) is currently trading at a premium valuation relative to its pharmaceutical peers, supported by strong revenue and earnings growth, robust profitability, and high returns on equity. Despite lofty multiples, the company's solid financial health and optimistic earnings forecasts underpin its valuation, with analysts generally bullish and projecting upside potential.
Valuation Metrics
Sentiment & Analyst Ratings
Eli Lilly (LLY) enjoys a positive market sentiment driven by strong financial results, robust growth in its GLP-1 franchise, and promising pipeline advancements. Analysts generally recommend buying, supported by bullish price targets and optimism around new drug launches. However, concerns about pricing pressure, competition, and regulatory risks introduce some caution among investors.
Analyst Recommendations
Risk Assessment
Eli Lilly displays strong revenue growth driven by its GLP-1 drugs but carries elevated financial risk due to high debt levels and pricing pressures. While its liquidity position remains stable, significant dependency on a few key drugs amidst an intensely competitive and regulated market presents material downside risks for investors.
Liquidity & Solvency
Frequently Asked Questions about LLY
AI Answers: Common Questions About LLY
Get AI-powered answers to the questions investors ask most about Eli Lilly and Company
LLY is a good buy for medium- and long-term investors seeking growth, as it trades at $1098.13 with a P/E of 38.98 and strong earnings momentum. While the valuation is high, it is supported by 44.7% YoY revenue growth and nearly 100% EPS growth, making it attractive if you are comfortable with premium multiples and some volatility.
Unless your thesis has changed or you need to rebalance, there is no strong reason to sell now. Fundamentals and technicals remain robust, and the uptrend is intact. However, if you are risk-averse or concerned about valuation compression, consider trimming if price approaches resistance near $1182.
The biggest risks are heavy dependence on GLP-1 drugs (over half of revenue), a high debt-to-equity ratio above 1.3, and exposure to regulatory or pricing changes. Any slowdown in growth, pipeline setbacks, or adverse regulatory action could lead to multiple compression and downside volatility.
Technically, resistance is at $1182.73 (52-week high), with support at $1011 (50 SMA) and $966 (200 SMA). Analysts' targets suggest ~14% upside from current levels, contingent on continued execution and pipeline progress.
LLY is trading at a significant premium (P/E 38.98, P/S and EV/EBITDA more than double peers), but this is justified by its superior growth and profitability. The stock is fairly valued relative to its prospects, but leaves little room for disappointment.
Fundamentals are exceptionally strong: revenue up 44.7% YoY, EPS up 96.2%, gross margins above 82%, net margins near 37%, and ROE approaching 40%. Free cash flow and balance sheet are robust, supporting ongoing investment and growth.
Technicals are bullish: price is in a strong uptrend, above all major moving averages, with RSI at 54 (neutral, not overbought). No reversal patterns are present; next resistance is at $1182.73, with support at $1011 and $966.
Key catalysts include upcoming earnings reports, new drug approvals (notably retatrutide and orforglipron), and further positive clinical data. Regulatory developments and pricing reforms are also important to monitor.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.